ACT-335827|cas:1354039-86-3|西域试剂

ACT-335827,98.0%

产品编号：Bellancom-108683| CAS NO：1354039-86-3| 分子式：C₃₁H₃₈N₂O₅| 分子量：518.64

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-108683		￥7300.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ACT-335827

产品介绍

ACT-335827 是一种选择性的、具有口服活性、可透过血脑屏障的 orexin 1 型 (orexin type 1) 受体拮抗剂。ACT-33582 作用于 OXR1 和 OXR2 的 IC₅₀ 值分别是 6 nM 和 417 nM。ACT-33582 可用于神经系统疾病的相关研究。

生物活性

ACT-335827 is a selective, orally active, brain-penetrant orexin type 1 receptor antagonist. ACT-33582 acts on OXR1 and OXR2 with IC₅₀ values of 6 nM and 417 nM, respectively. ACT-33582 can be used in studies related to neurological disorders.

体外研究

ACT-335827 (0-10 μM, 2 h) acts on OXR-1 and OXR-2 with the K_b values of 41 nM and 560 nM, the IC₅₀ values of 120 nM and 2300 nM, respectively in CHO cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ACT-335827 (oral gavage, 30-100 mg/kg, once) can reduce the fear-induced startle response with no affecting motor or cognitive function in rats.
ACT-335827 (oral administration, 300 mg/kg, everyday, 4 weeks) has less effect on metabolic syndrome (MetS), such as diet-induced obesity (DIO) in male Wistar rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats
Dosage:	30, 100 or 300 mg/kg
Administration:	Oral gavage; once
Result:	Reduced fear-induced startle response at 300 mg/kg. Decreased stress-induced elevated body temperature at 300 mg/kg and accelerated heat rate at 100 or 300 mg/kg but no effect on locomotion and blood pressure.

Animal Model:	Male Wistar rats weighing160-180g
Dosage:	300 mg/kg
Administration:	Oral administration; everyday; 4 weeks
Result:	Reduced preference for high fat/sweet diets but no effect on absolute energy intake. Increased water intake and HDL relative to total cholesterol. Resulted in a 4% weight gain compared to the control group.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats
Dosage:	30, 100 or 300 mg/kg
Administration:	Oral gavage; once
Result:	Reduced fear-induced startle response at 300 mg/kg. Decreased stress-induced elevated body temperature at 300 mg/kg and accelerated heat rate at 100 or 300 mg/kg but no effect on locomotion and blood pressure.

Animal Model:	Male Wistar rats weighing160-180g
Dosage:	300 mg/kg
Administration:	Oral administration; everyday; 4 weeks
Result:	Reduced preference for high fat/sweet diets but no effect on absolute energy intake. Increased water intake and HDL relative to total cholesterol. Resulted in a 4% weight gain compared to the control group.